Lunsumio (mosunetuzumab-axgb) / Roche, Biogen - LARVOL DELTA

MosuOSSHSR: Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP). (clinicaltrials.gov) - P=N/A | N=25 | Not yet recruiting | Sponsor: Andrés José Maria Ferreri

New trial • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

Hematotoxicity and immune deficits with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma (ASH 2025) - "Among NHL cohorts, the BsAb distribution was: 7 glofitamab, 6 mosunetuzumab, 5 epcoritamab, and 4 odronextamab. Among MM cohorts, 6 received teclistamab, 3 talquetamab, 1 teclistamab and talquetamab, 2 elranatamab, 2 linvoseltamab and 1 etentamig (ABBV-383)... Cytopenias affect a substantial proportion of patients treated with BsAbs, particularly in MM and in NHL with combination regimes. These findings support the need for systematic hematologic monitoring, IG surveillance and tailored pre-emptive strategies to mitigate infection risk.This study represents the first and most comprehensive meta-analysis of hematotoxicity and immune deficits with BsAbs, establishing a benchmark across clinical settings."

Retrospective data • Review • Hematological Malignancies • Infectious Disease • Lymphoma • Multiple Myeloma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia

Cardiovascular adverse events associated with bispecific antibodies in Relapsed/Refractory hematologic malignancies: A comprehensive systematic review and meta-analysis (ASH 2025) - "The study included seven bispecific antibodies (BsAbs) : blinatumomab , mosunetuzumab , elranatamab , epcoritamab , glofitamab , talquetamab , and teclistamab . While bispecific antibodies (BsAbs) show promising results in managing R/R hematologic malignancies, their use can lead to significant cardiac adverse effects, including tachycardia, arrhythmias, and hypotension. To mitigate these risks, a multidisciplinary approach—incorporating vigilant cardiac monitoring, preventive strategies, and prompt intervention—is essential for optimizing patient care and treatment success. Risk of Bias was relatively low."

Adverse events • Retrospective data • Review • Atrial Fibrillation • B Cell Lymphoma • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Malignancies • Hypertension • Hypotension • Lymphoma • Myocardial Infarction • Non-Hodgkin’s Lymphoma • Oncology

Incidence of second primary malignancies (SPMs) following bispecific antibody (BsAb) therapy for lymphoid malignancies: A descriptive analysis of clinical trials (ASH 2025) - "Included agents were blinatumomab (CD19×CD3), glofitamab, mosunetuzumab, epcoritamab, and odronextamab (all CD20×CD3), as well as elranatamab, teclistamab, and linvoseltamab (BCMA×CD3), and talquetamab (GPRC5DxCD3). Notably, some reported cases may represent disease progression rather than true SPMs. However, limited follow-up duration across trials warrants continued long-term surveillance, particularly as agents move to frontline settings where longer survival may reveal delayed malignancies."

Clinical • Acute Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lung Cancer • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • CD20

Effectiveness and safety of bispecific antibodies in relapsed/refractory diffuse large B-cell lymphoma (DLBCL): A systematic review and meta-analysis (ASH 2025) - " Twelve eligible studies involving 744 patients were included, primarily evaluating glofitamab (6 studies), epcoritamab (2), mosunetuzumab (2), and odronextamab (2). Bispecific antibodies offer a promising therapeutic approach for relapsed/refractory DLBCL, particularly in heavily pretreated or CAR-T-ineligible patients. These findings support their expanding role in clinical practice and highlight the need for further real-world evidence. Multi-national randomized controlled trials with longer follow-up are needed to establish durability and optimize treatment sequencing."

Retrospective data • Review • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma

Physicians perceptions of fixed-duration epcoritamab + lenalidomide and rituximab regimens in relapsed/refractory follicular lymphoma: Insights from the epcore NHL-2 trial (ASH 2025) - "Before reviewing trial data, despite 40% reporting BsAb use, only 29% reported they would select BsAbs (i.e., mosunetuzumab, epcoritamab) as their preferred 3L regimen for a hypothetical patient with R/R FL (65-year-old male, stage III, and an ECOG PS of 1 who received R-CHOP in 1L and bendamustine + rituximab in 2L), and most respondents preferred CAR T therapy (42%) for this patient. U.S. oncologists demonstrated increased interest in the fixed duration of ER2 following review of EPCORE NHL-2 data, with a notable shift in preference from CAR T to BsAbs in earlier lines of treatment for R/R FL. The regimen's defined treatment duration and potential for use in 2L settings were key drivers of interest. These findings suggest that ER2 may offer a clinically attractive alternative to existing therapies, particularly for patients' ineligible for CAR T or those seeking outpatient, time-limited options."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma

Cardiovascular safety profile of CD20 × CD3 bispecific antibodies compared to immune-checkpoint inhibitors: A faers analysis, 2014–2025 (ASH 2025) - "Background: Bispecific T-cell engagers (BTEs) have evolved from CD19 × CD3 constructs such as blinatumomab to newer CD20 × CD3 agents, including mosunetuzumab, glofitamab, and epcoritamab. CD20 × CD3 bispecifics are associated with a distinct arrythmia signal, more frequent and earlier than that observed with ICIs. However, overall arrhythmia reporting has declined over time, likely reflecting improved mitigation strategies such as step-up dosing and early monitoring. Nonetheless, the absolute incidence (2.8%) exceeds that seen with ICIs, supporting baseline ECG and rhythm surveillance during CD20 BTE initiation."

Checkpoint inhibition • Clinical • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Disorders • Inflammation • Oncology • Venous Thromboembolism • CD20 • ROR1

Real-world descriptive analysis of the use of bispecific t cell engagers (BiTEs) in the treatment of hematological malignancies in Qatar: A state-wide retrospective cohort study (ASH 2025) - "Nevertheless, in r/r multiple myeloma (MM) elranatamab and teclistamab have been used to target BCMA. Another BiTE targeting CD20 used in r/r follicular lymphoma (FL) such as mosunetuzumab, and glofitamab in r/r diffuse large B cell lymphoma (DLBCL), while epcoritamab has been approved in both indications (Shouse G., 2025)...Method This is a descriptive retrospective cohort study, including all adult hematological patients who were treated with BiTEs: epcoritamab, glofitamab, blinatumomab, and teclistamab...Despite the small sample size and the study design, our findings nearly comply with primary literature that BiTEs serve as a promising therapeutic alternative for patients with relapsed or refractory disease, particularly those who have exhausted other modalities. However, the high incidence of reported adverse drug reactions (ADRs), including severe toxicities such as CRS and ICANS, highlights the need for robust and careful strategies for safety and tolerability..."

Real-world • Real-world evidence • Retrospective data • Acute Lymphocytic Leukemia • B Cell Lymphoma • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma

Mosunetuzumab in combination with zanubrutinib is safe in patients with relapsed/refractory follicular lymphoma: Safety run-in results from the FIL-mozart Phase II study (ASH 2025) - "Only one pt, with G2 CRS, required tocilizumab and was cautiously hospitalized, resulting in the only SAE of the cohort. Preliminary efficacy is encouraging and overall data supports further study of this regimen in R/R FL. RT and ML share first authorship"

Clinical • Combination therapy • P2 data • Dermatology • Dyspepsia • Febrile Neutropenia • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia

Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study (ASH 2025) - No abstract available

Clinical • Combination therapy • P1/2 data • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis (ASH 2025) - No abstract available

Clinical • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma

Promote-FL: Pirtobrutinib and mosunetuzumab to enhance treatment efficacy for patients with relapsed/refractory follicular lymphoma (ASH 2025) - P2 | "For instance, zanubrutinib, a newergeneration covalent BTK inhibitor (BTKi), showed an improved overall response rate (ORR) in combinationwith obinutuzumab compared to obinutuzumab alone (69% versus 46%) in the ROSEWOOD trial.Pirtobrutinib (pirto), a non-covalent BTKi, has also demonstrated an ORR of 50% in FL based on theBRUIN trial. If successful, itwill provide a more efficacious and safer treatment option in heavily treated FL. This approach (addingBTKi) may be applied more broadly in T cell-based immunotherapy in B cell lymphoma."

Clinical • B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Immunology • Lymphoma • Non-Hodgkin’s Lymphoma

Pooled analysis of early-Phase trials highlights robust activity of CD3-CD20 T-cell engagers in follicular lymphoma (ASH 2025) - "It was not feasible to compare monotherapy withcombination therapy trials due to limitations in the reported risk categories of patients enrolled.R/R FL: In the relapsed setting, Epcoritamab was included in 3 trials (one of which was incombination with lenalidomide and rituximab (R2)), Mosunetuzumab in 2, Glofitamab in 1, andOdronextamab in 1. This pooled analysis confirms that CD3-CD20 TCE therapies achieve high overall andcomplete response rates in FL. This is particularly seen in the frontline setting. Responses in R/R werealso clinically meaningful and durable, especially given that most trials enrolled patients with at least 2 ormore previous lines of therapy."

Retrospective data • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • CD20

Real world efficacy of mosunetuzumab in follicular lymphoma patients previously exposed to lenalidomide: A collaborative US bispecifics consortium study (ASH 2025) - "In this first real-world multi-center study, prior lenalidomide exposure does not seem toimpact safety and efficacy of mosunetuzumab in patients with FL. Longer follow up and cohorts includinga larger fraction of patients with recent (< 24 months) lenalidomide exposure are needed to confirmthese hypothesis-generating findings."

Clinical • IO biomarker • Real-world • Real-world effectiveness • Real-world evidence • Follicular Lymphoma • Hematological Malignancies • Lymphoma

Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study (ASH 2025) - P1/2 | "In this updated analysis, with a median follow-up of 35.5 months, fixed-duration Mosun SCcontinued to demonstrate durable responses, similar to those previously reported for Mosun IV in acomparable patient population. The safety profile was manageable with low rates of CRS and infections,consistent with previous analyses. Mosun SC has a favorable benefit-risk profile with the convenience ofoutpatient accessibility and short administration times."

Clinical • P2 data • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Febrile Neutropenia • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Lymphoma • Neutropenia • Pneumonia • Rare Diseases • Respiratory Diseases

Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study (ASH 2025) - P1/2 | "This report represents the longest follow-up for a CD20xCD3 bispecific antibody in R/R FL.Fixed-duration mosunetuzumab treatment yields durable responses, and long-term survival continues tobe observed in patients with heavily pre-treated R/R FL. The data highlight the durable long-termremissions achieved with mosunetuzumab in this setting. Updated data confirm that B-cell recovery isobserved and sustained."

Clinical • P2 data • Cardiovascular • Follicular Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Septic Shock

Risk factors for failure to complete step-up-dosing of bispecific antibody therapy for B-cell lymphomas (ASH 2025) - "Among LBCL pts, 31 (45.6%) received glofitamab (glofit), 31 (45.6%) epcoritamab (epco), and6 (8.8%) mosunetuzumab (mosun). Our findings suggest a substantial percentage (20%) of pts with LBCL do not make it to thefull dose of BsAb therapy. Risk factors, such as elevated LDH and LBCL histology, characterize a subset ofpts, at high-risk for not completing SUD and early mortality, which may necessitate an alternative txstrategy. Efficacious "bridging" or pre-BsAb therapy could be a reasonable approach to improvingoutcomes for these high-risk pts."

Clinical • B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • CD20

Real-world multicenter outcomes of CD3xCD20 bispecific antibody therapies in patients with central nervous system (CNS) lymphoma (ASH 2025) - "Progression-free survival (PFS) was calculated fromBsAb initiation to disease progression (PD) or death, and overall survival (OS) from BsAb initiation todeath.We included 20 pts who received BsAb (glofitamab n=15, epcoritamab n=3, mosunetuzumab n=2) from9/2023 to 11/2024. Twelve pts received BsAb alone and 8 combined with systemic therapy(acalabrutinib/zanubrutinib n=4, polatuzumab n=3) and/or radiation (RT, n=4).Median age was 68 years, 55% were male, and 45% had ECOG ≥2... Our study shows significant clinical activity for the CD3xCD20 BsAb, alone and in combination, in B-NHLwith CNS involvement (CNS-specific ORR and CR rate of 55% and 27%, respectively) without new safetyconcerns. Larger studies, ideally prospective, are needed to confirm the efficacy and safety of CD3xCD20BsAb in pts with CNS involvement by B-NHL."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • CNS Disorders • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma

Improvements in health-related quality of life (HRQoL) in the SUNMO study: Subcutaneous (SC) mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) vs rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after at least one prior therapy (ASH 2025) - P3 | "In SUNMO, Mosun-Pola provided benefits across multiple aspects of HRQoL compared withR-GemOx, particularly in maintaining/improving physical functioning, fatigue, lymphoma symptoms, andPN. Pts treated with Mosun-Pola achieved clinically meaningful improvements in PROs, with scoresexceeding the MCID in several domains and exhibiting a delay in deterioration of >1 year for physicalfunctioning, and >2 months for PN and lymphoma symptoms. Improved PROs with Mosun-Pola vs R-GemOx suggest benefits in HRQoL with chemotherapy-free bispecific antibody combinations."

Clinical • HEOR • B Cell Lymphoma • Gastroenterology • Gastrointestinal Disorder • Gynecologic Cancers • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral Neuropathic Pain

Favorable preliminary safety and efficacy of mosunetuzumab plus ICE or DHAX salvage chemotherapy in relapsed/refractory large B-cell lymphoma (ASH 2025) - P1 | "With universal prior rituximab exposure in pts withR/R LBCL, salvage strategies may be improved by incorporating novel agents instead of rituximabretreatment...All pts receive at least 2 cyclesof concurrent Mosun + platinum-based chemotherapy, with chemotherapy per treating physician (Arm A:dexamethasone, cytarabine, oxaliplatin [DHAX]; Arm B: ifosfamide, carboplatin, etoposide [ICE])...Pts receive 20mg IV dexamethasone prior to each C1-C2Mosun dose, with optional steroid premeds thereafter...Nine pts experienced CRS (all gr1; no tocilizumab required)... Mosun + DHAX/ICE demonstrated a manageable safety profile with low-grade CRS.Preliminary efficacy results reveal promising anti-lymphoma activity in a high-risk population, with highCR rate and no progressions after CR with relatively short follow-up. This regimen is encouraging forfurther study. Long-term efficacy data are awaited to better assess remission durability."

Clinical • B Cell Lymphoma • Cardiovascular • CNS Disorders • CNS Lymphoma • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hepatology • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Psychiatry • Septic Shock • Thrombocytopenia • Thrombosis • CD20

Pattern of infections and impact on immunocompetence of next generation B-cell depleting immunotherapies in non-Hodgkin's lymphomas: Results from a multicentre retrospective real- life cohort. (ASH 2025) - "All patients diagnosed with NHL in three Italian centers, who started thetreatment from Dec 1st, 2019 to Apr 30th, 2025 were consecutively included in the analysis. 110 NHL patients were treated with 131 lines of immunotherapies, including 91 with antiCD19CAR-T cells (46 Axi-cel, 29 Tisa-cel, 16 Brexu-cel), 30 with antiCD20/antiCD3 bispecific MoAbs (10glofitamab, 14 epcoritamab and 6 mosunetuzumab), and 10 with AntiCD19 ADC (loncastuximab). Infections are common complications during novel immunotherapy treatments in NHL:nonetheless, in our real-life cohort most of cases occurred early (< 100 days) and showed manageablemild-moderate severity. Overall, in this setting of relapsed/refractory NHL patients the main cause ofdeath remains lymphoma progression."

Retrospective data • Dermatology • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • High-grade B-cell lymphoma • Immunology • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Pneumonia • Primary Mediastinal Large B-Cell Lymphoma • Respiratory Diseases

BMS-986458, a first-in-class, highly selective, and potent ligand-directed degrader (LDD) of B-cell lymphoma 6 (BCL6) combined with T-cell engagers (TCEs) demonstrates preclinical synergistic antitumor efficacy for the treatment of B-cell non-Hodgkin lymphoma (NHL) (ASH 2025) - P1/2 | "3 daysafter hPBMC injection, mice were randomized in 4 groups (8–9 per group): vehicle, BMS-986458 (5 mg/kgBID PO), glofitamab (glofit; 1 µg/mouse IV QW), and combination (BMS-986458+glofit)... In vitro anti-tumor response to BMS-986458 + 3 CD20xCD3 TCEs (glofit, epcoritamab, andmosunetuzumab) was evaluated in 3 cell lines... Combining BMS-986458 with TCEs results in synergistic T cell-driven tumor cell killing acrossmultiple DLBCL models. In vivo, using a hPBMC mouse DLBCL model, BMS-986458+glofit demonstratedsynergistic antitumor efficacy, and increased infiltration of CD3 T cells into the tumor microenvironment.No evidence of T-cell activation based on HLA-DR expression or plasma-measured cytokines wasobserved with BMS-986458±glofit. In vitro studies showed synergy was observed irrespective of CD20fold-induction following BMS-986458 treatment, and was also observed in models lacking BCL6expression, indicating that additional immune mechanisms may be..."

Preclinical • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL6 • CD20 • CD4 • CD69 • CD8 • CRBN • CXCL8 • IFNG • IL10 • IL1B • IL2 • IL4 • IL6 • TNFA

Outcomes of CAR T-cell therapies after prior treatment with fixed-duration mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (ASH 2025) - P1/2 | "Two (9.1%) pts received bendamustinewithin 12 mo prior to leukapheresis and 3 (13.6%) pts received bridging therapy (radiation [RT], n=2; RTand venetoclax, n=1). The CAR T-cell therapies received were axicabtagene ciloleucel (n=12),brexucabtagene autoleucel (n=3), tisagenlecleucel (n=2), lisocabtagene maraleucel (n=1), and aninvestigational CD19-targeted CAR T-cell therapy (n=4)... This real-world multicenter analysis suggests that prior Mosun treatment does not impairthe efficacy of subsequent CAR T-cell therapy in pts with R/R B-NHL, with the safety profile consistentwith previously published data. These results support CAR T-cell therapy as a viable treatment optionfollowing BsAb treatment. Further studies are needed to fully characterize and validate the efficacy andsafety of CAR T-cell therapy after BsAbs such as Mosun."

CAR T-Cell Therapy • Clinical • Acute Kidney Injury • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Pneumonia • Renal Disease • Respiratory Diseases • Septic Shock

A US real-world analysis of demographics, transplant patterns, and survival outcomes in posttransplant lymphoproliferative disorder (PTLD) (ASH 2025) - "Other agents includedprednisone (6.2%), cyclosporine (5.8%), sirolimus (5.8%), dexamethasone (4.8%), azathioprine (3.1%),methylprednisolone (1.9%), everolimus (0.7%), ibrutinib (0.6%), ruxolitinib (0.6%), mycophenolate(0.3%), basiliximab (0.2%), and thymoglobulin (0.1%).Extranodal, bone marrow, and CNS involvement were present in 29.5%, 1.9%, and 1.8% of cases,respectively...Median OSfor heart transplant recipients was 2730 days, and for those who underwent HSCT, 2643 days.Regarding treatment, only 10 patients received bispecific antibodies (glofitamab, epcoritamab, ormosunetuzumab) and only 23 patients received CAR-T therapy. This study represents one of the largest real-world analyses of PTLD in adult patients inthe US, utilizing the TriNetX dataset spanning over three decades. This study represents one of the largest real-world analyses of PTLD in adult patients inthe US, utilizing the TriNetX dataset spanning over three decades. Improvement in OS in more recentyears..."

Clinical • Post-transplantation • Real-world • Real-world evidence • Bone Marrow Transplantation • Epstein-Barr Virus Infections • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Solid Organ Transplantation • Transplantation

Spatially resolved profiling reveals the perifollicular border zone as a key immunologic hub in follicular lymphoma undergoing mosunetuzumab therapy (ASH 2025) - P2 | "They received Mosun for 4 cycles, followed by Mosun alone in case of interim complete response(CR) or Mosun + lenalidomide otherwise. This spatial analysis of TME identifies the perifollicular BZ as a hub for T cell recruitmentand activity in FL, expanding during mosunetuzumab therapy. Increased macrophage content and T cellregulatory mechanisms occurring on therapy support exploration of rational BsAb-based combinationswith agents that modulate T cell function, macrophage activity, or immune checkpoints to enhancetherapeutic efficacy."

IO biomarker • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Nodal Marginal Zone Lymphoma • CCL19 • CCR7 • CD20 • CD27 • CD63 • CD69 • CD70 • CD8 • CD80 • CTLA4 • CXCL10 • CXCL9 • GZMB • HAVCR2 • IL7R • ITGAX • LAG3 • LAMP3 • LCK • LGALS9 • PD-1 • TCF7 • VSIR • ZAP70